Peter Veng-Pedersen - Publications

Affiliations: 
Pharmacy University of Iowa, Iowa City, IA 
Area:
Pharmacy, Cell Biology

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 D'Cunha R, Schmidt R, Widness JA, Mock DM, Yan X, Cress GA, Kuruvilla D, Veng-Pedersen P, An G. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 105013. PMID 31340188 DOI: 10.1016/j.ejps.2019.105013  0.8
2019 Li X, Wu X, Kelly KM, Veng-Pedersen P, Lehmler HJ. Toxicokinetics of Chiral PCB 136 and its Hydroxylated Metabolites in Mice with a Liver-Specific Deletion of Cytochrome P450 Reductase. Chemical Research in Toxicology. PMID 30729780 DOI: 10.1021/acs.chemrestox.8b00389  0.36
2019 D'Cunha R, Widness JA, Yan X, Schmidt RL, Veng-Pedersen P, An G. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses. Journal of Clinical Pharmacology. PMID 30618050 DOI: 10.1002/jcph.1368  0.8
2018 An G, Schmidt RL, Mock DM, Veng-Pedersen P, Widness JA. Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin. The Aaps Journal. 21: 6. PMID 30478521 DOI: 10.1208/s12248-018-0269-7  0.8
2018 Mock DM, Nalbant D, Kyosseva SV, Schmidt RL, An G, Matthews NI, Vlaar APJ, van Bruggen R, de Korte D, Strauss RG, Cancelas JA, Franco RS, Veng-Pedersen P, Widness JA. Development, validation, and potential applications of biotinylated red blood cells for posttransfusion kinetics and other physiological studies: evidenced-based analysis and recommendations. Transfusion. PMID 29770455 DOI: 10.1111/trf.14647  0.8
2017 An G, Ohls RK, Christensen RD, Widness JA, Mock DM, Veng-Pedersen P. Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of Pharmaceutical Sciences. PMID 28189627 DOI: 10.1016/j.xphs.2017.02.001  0.8
2017 Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, An G, Veng-Pedersen P. Estimation of Adult and Neonatal RBC Lifespans in Anemic Neonates using RBCs Labeled at Several Discrete Biotin Densities. Pediatric Research. PMID 28099421 DOI: 10.1038/pr.2017.14  0.8
2016 An G, Widness JA, Mock DM, Veng-Pedersen P. A Novel Physiology-Based Mathematical Model to Estimate Red Blood Cell Lifespan in Different Human Age Groups. The Aaps Journal. PMID 27215601 DOI: 10.1208/s12248-016-9923-0  0.8
2016 Shrestha RP, Horowitz J, Hollot CV, Germain MJ, Widness JA, Mock DM, Veng-Pedersen P, Chait Y. Models for the red blood cell lifespan. Journal of Pharmacokinetics and Pharmacodynamics. PMID 27039311 DOI: 10.1007/s10928-016-9470-4  0.8
2015 Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, Veng-Pedersen P. A Mass Balance-Based Semiparametric Approach to Evaluate Neonatal Erythropoiesis. The Aaps Journal. PMID 26502725 DOI: 10.1208/s12248-015-9831-8  0.8
2015 Widness JA, Kuruvilla DJ, Mock DM, Matthews NI, Nalbant D, Cress GA, Schmidt RL, Strauss RG, Zimmerman MB, Veng-Pedersen P. Autologous Infant and Allogeneic Adult Red Cells Demonstrate Similar Concurrent Post-Transfusion Survival in Very Low Birth Weight Neonates. The Journal of Pediatrics. PMID 26363547 DOI: 10.1016/j.jpeds.2015.08.028  0.8
2015 Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, Veng-Pedersen P. A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs. The Aaps Journal. PMID 26017162 DOI: 10.1208/s12248-015-9784-y  0.8
2015 Kulshrestha M, Sola-Visner M, Widness JA, Veng-Pedersen P, Mager DE. Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates. American Journal of Physiology. Heart and Circulatory Physiology. 308: H68-73. PMID 25362135 DOI: 10.1152/ajpheart.00528.2013  0.8
2014 Mock DM, Widness JA, Veng-Pedersen P, Strauss RG, Cancelas JA, Cohen RM, Lindsell CJ, Franco RS. Measurement of posttransfusion red cell survival with the biotin label. Transfusion Medicine Reviews. 28: 114-25. PMID 24969019 DOI: 10.1016/j.tmrv.2014.03.003  0.8
2014 Kuruvilla DJ, Nalbant D, Widness JA, Veng-Pedersen P. Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells. Transfusion. 54: 2724-9. PMID 24611672 DOI: 10.1111/trf.12562  0.8
2014 Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan Blood. 123: 3381-3389. PMID 24599546 DOI: 10.1182/blood-2013-06-508200  0.8
2014 Rosebraugh MR, Widness JA, Nalbant D, Cress G, Veng-Pedersen P. Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatric Research. 75: 336-42. PMID 24216541 DOI: 10.1038/pr.2013.213  0.8
2013 Saleh MI, Nalbant D, Widness JA, Veng-Pedersen P. Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 304: R772-81. PMID 23485870 DOI: 10.1152/ajpregu.00173.2012  0.8
2013 Rosebraugh MR, Widness JA, Nalbant D, Veng-Pedersen P. A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia. Transfusion. 53: 1353-60. PMID 23033916 DOI: 10.1111/j.1537-2995.2012.03908.x  0.8
2012 Kania-Korwel I, Barnhart CD, Stamou M, Truong KM, El-Komy MH, Lein PJ, Veng-Pedersen P, Lehmler HJ. 2,2',3,5',6-Pentachlorobiphenyl (PCB 95) and its hydroxylated metabolites are enantiomerically enriched in female mice. Environmental Science & Technology. 46: 11393-401. PMID 22974126 DOI: 10.1021/es302810t  0.8
2012 Rosebraugh MR, Widness JA, Veng-Pedersen P. Multidose optimization simulation of erythropoietin treatment in preterm infants. Pediatric Research. 71: 332-7. PMID 22391632 DOI: 10.1038/pr.2011.75  0.8
2012 Mock DM, Matthews NI, Zhu S, Strauss RG, Schmidt RL, Zimmerman MB, Nalbant D, Freise KJ, Saleh M, Veng-Pedersen P, Widness JA. Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease. Transfusion. 52: 963-73. PMID 22229348 DOI: 10.1111/j.1537-2995.2011.03512.x  0.8
2011 Lin CW, Warram JH, Veng-Pedersen P. A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents. Journal of Pharmacokinetics and Pharmacodynamics. 38: 563-79. PMID 21833670 DOI: 10.1007/s10928-011-9208-2  0.92
2011 El-Komy MH, Schmidt RL, Widness JA, Veng-Pedersen P. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep. Biopharmaceutics & Drug Disposition. 32: 276-88. PMID 21678432 DOI: 10.1002/bdd.757  0.8
2011 Rosebraugh M, Widness JA, Veng-Pedersen P. Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1214-20. PMID 21460232 DOI: 10.1124/dmd.110.036855  0.8
2011 Saleh MI, Widness JA, Veng-Pedersen P. Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep. Biopharmaceutics & Drug Disposition. 32: 131-9. PMID 21456051 DOI: 10.1002/bdd.743  0.8
2011 El-Komy MH, Widness JA, Veng-Pedersen P. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 603-9. PMID 21209249 DOI: 10.1124/dmd.110.036236  0.8
2010 Xie L, Hoffman RP, Veng-Pedersen P. Population analysis of ethnicity and first-phase insulin release. Diabetes Research and Clinical Practice. 89: 243-9. PMID 20570007 DOI: 10.1016/j.diabres.2010.04.025  0.6
2010 Mock DM, Matthews NI, Zhu S, Burmeister LF, Zimmerman MB, Strauss RG, Schmidt RL, Nalbant D, Freise KJ, Veng-Pedersen P, Widness JA. Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotin. Transfusion. 50: 2553-64. PMID 20561297 DOI: 10.1111/j.1537-2995.2010.02744.x  0.8
2010 Kania-Korwel I, El-Komy MH, Veng-Pedersen P, Lehmler HJ. Clearance of polychlorinated biphenyl atropisomers is enantioselective in female C57Bl/6 mice. Environmental Science & Technology. 44: 2828-35. PMID 20384376 DOI: 10.1021/es901781p  0.56
2010 Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. The Journal of Pharmacology and Experimental Therapeutics. 333: 528-32. PMID 20103588 DOI: 10.1124/jpet.109.163568  0.8
2010 Freise KJ, Widness JA, Veng-Pedersen P. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants. The Journal of Pharmacology and Experimental Therapeutics. 332: 229-37. PMID 19808699 DOI: 10.1124/jpet.109.159905  0.8
2009 Lin CW, Veng-Pedersen P. Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics. Journal of Pharmacokinetics and Pharmacodynamics. 36: 421-41. PMID 19756980 DOI: 10.1007/s10928-009-9130-z  0.92
2009 Neelakantan S, Widness JA, Schmidt RL, Veng-Pedersen P. Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia. Pediatrics International : Official Journal of the Japan Pediatric Society. 51: 25-32. PMID 19371274 DOI: 10.1111/j.1442-200X.2008.02648.x  1
2009 Xie L, Hoffman RP, Veng-Pedersen P. Noncompartmental pharmacokinetics analysis of glucose-stimulated insulin response in African-American and Caucasian youths. Biopharmaceutics & Drug Disposition. 30: 117-25. PMID 19288584 DOI: 10.1002/bdd.652  0.6
2009 Freise KJ, Schmidt RL, Gingerich EL, Veng-Pedersen P, Widness JA. The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time. International Journal of Laboratory Hematology. 31: 496-504. PMID 18422712 DOI: 10.1111/j.1751-553X.2008.01066.x  0.8
2008 Freise KJ, Schmidt RL, Widness JA, Veng-Pedersen P. Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response. Journal of Pharmacokinetics and Pharmacodynamics. 35: 527-52. PMID 18937059 DOI: 10.1007/s10928-008-9100-x  0.8
2008 Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. The Journal of Pharmacy and Pharmacology. 60: 1321-34. PMID 18812025 DOI: 10.1211/jpp/60.10.0008  0.8
2008 Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep. Journal of Pharmacokinetics and Pharmacodynamics. 35: 285-323. PMID 18553126 DOI: 10.1007/s10928-008-9089-1  0.8
2007 Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep. Journal of Pharmacokinetics and Pharmacodynamics. 34: 519-47. PMID 17516153 DOI: 10.1007/s10928-007-9056-2  0.8
2007 Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy. Pharmaceutical Research. 24: 1653-9. PMID 17457660 DOI: 10.1007/s11095-007-9295-3  0.8
2007 Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation Clinical Pharmacology and Therapeutics. 81: 873-879. PMID 17429351 DOI: 10.1038/sj.clpt.6100165  0.8
2007 Gupta N, Al-Huniti NH, Veng-Pedersen P. Individualized pharmacokinetic risk assessment for development of diabetes in high risk population. Diabetes Research and Clinical Practice. 78: 93-101. PMID 17368857 DOI: 10.1016/j.diabres.2007.02.013  0.8
2006 Neelakantan S, Widness JA, Schmidt RL, Veng-Pedersen P. A 'bottom-up' approach for endo-PK/PD analysis. Biopharmaceutics & Drug Disposition. 27: 313-27. PMID 16892181 DOI: 10.1002/bdd.508  1
2006 Durairaj L, Neelakantan S, Launspach J, Watt JL, Allaman MM, Kearney WR, Veng-Pedersen P, Zabner J. Bronchoscopic assessment of airway retention time of aerosolized xylitol. Respiratory Research. 7: 27. PMID 16483382 DOI: 10.1186/1465-9921-7-27  0.8
2005 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. Journal of Pharmacokinetics and Pharmacodynamics. 32: 359-76. PMID 16284920 DOI: 10.1007/s10928-005-0009-3  0.8
2005 Neelakantan S, Veng-Pedersen P. Determination of drug absorption rate in time-variant disposition by direct deconvolution using beta clearance correction and end-constrained non-parametric regression. Biopharmaceutics & Drug Disposition. 26: 353-70. PMID 16088968 DOI: 10.1002/bdd.468  1
2004 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Erythropoietin production rate in phlebotomy-induced acute anemia. Biopharmaceutics & Drug Disposition. 25: 389-97. PMID 15529399 DOI: 10.1002/bdd.424  0.8
2004 Bechensteen AG, Chapel S, Veng-Pedersen P, Widness JA. Posttransfusion recovery of stored red blood cells in very low birth weight infants using a hemoglobin balance model. Transfusion. 44: 1019-24. PMID 15225242 DOI: 10.1111/j.1537-2995.2004.03376.x  0.8
2004 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schimdt RL, Sedars EM, Hohl RJ, Widness JA. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phylebotomy-induced anemia and bone marrow ablation Biopharmaceutics and Drug Disposition. 25: 149-156. PMID 15108217 DOI: 10.1002/bdd.395  0.8
2004 Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. The Journal of Pharmacology and Experimental Therapeutics. 310: 202-8. PMID 14988424 DOI: 10.1124/jpet.104.066027  0.8
2003 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep Journal of Pharmacology and Experimental Therapeutics. 306: 532-537. PMID 12750427 DOI: 10.1124/jpet.103.052431  0.8
2001 Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, Mcguire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway Journal of Pharmacology and Experimental Therapeutics. 298: 820-824. PMID 11454947  0.8
2001 Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Experimental Hematology. 29: 425-31. PMID 11301182  0.8
2000 Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. The Journal of Pharmacology and Experimental Therapeutics. 295: 346-51. PMID 10992000  0.8
Show low-probability matches.